NIH × Sezary Syndrome × Clear all
NCT02978625 2026-03-18

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

National Cancer Institute (NCI)

Phase 2 Active not recruiting
68 enrolled
NCT01567709 2018-04-11

Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
34 enrolled
NCT01254578 2017-09-25

Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers

National Cancer Institute (NCI)

Phase 1 Completed
17 enrolled
NCT00112723 2016-08-08

Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

National Cancer Institute (NCI)

Phase 1/2 Terminated
46 enrolled 12 charts
NCT00608361 2015-07-02

Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 1 Completed
80 enrolled
NCT00060021 2015-04-30

Acupuncture in Treating Mucositis-Related Pain Caused by Chemotherapy in Patients Undergoing Stem Cell Transplantation

National Cancer Institute (NCI)

Phase NA Completed
NCT00002765 2015-04-29

Immunotoxin in Treating Patients With Leukemia or Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
NCT00003993 2015-04-29

Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
24 enrolled
NCT00019344 2015-04-29

Flavopiridol in Treating Patients With Refractory Cancer

National Cancer Institute (NCI)

Phase 1 Completed
NCT00003210 2015-04-15

Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease

National Cancer Institute (NCI)

Phase 2 Completed
105 enrolled
NCT01158274 2014-11-07

RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
30 enrolled
NCT00933985 2014-05-01

Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

National Cancer Institute (NCI)

Phase 1 Terminated
22 enrolled
NCT01231919 2014-04-29

MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

National Cancer Institute (NCI)

Phase 1 Completed
45 enrolled
NCT00096005 2014-02-24

Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

National Cancer Institute (NCI)

Phase 1 Terminated
36 enrolled
NCT00101205 2014-02-24

Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Terminated
40 enrolled
NCT00499811 2014-02-24

Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction

National Cancer Institute (NCI)

Phase 1 Completed
15 enrolled
NCT00458731 2014-02-19

Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma

National Cancer Institute (NCI)

Phase 1 Completed
57 enrolled
NCT00769288 2014-01-07

FAU in Treating Patients With Advanced Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled
NCT00008307 2014-01-06

Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders

National Cancer Institute (NCI)

Phase 2 Unknown
52 enrolled
NCT00020865 2013-12-19

Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia

National Cancer Institute (NCI)

Phase 3 Unknown
NCT00008164 2013-12-18

Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia

National Cancer Institute (NCI)

Phase 2 Unknown
30 enrolled
NCT00769613 2013-12-18

Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections

National Cancer Institute (NCI)

Phase 1 Unknown
20 enrolled
NCT00293345 2013-09-30

3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
30 enrolled
NCT00023816 2013-09-20

Carbendazim in Treating Patients With Advanced Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Unknown
NCT00324597 2013-09-17

AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Unknown
18 enrolled
NCT00445497 2013-08-12

Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia

National Cancer Institute (NCI)

Phase 3 Unknown
400 enrolled
NCT00637637 2013-08-12

External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases

National Cancer Institute (NCI)

Phase 2 Unknown
60 enrolled
NCT01295463 2013-08-12

Study of Information Received About Fertility and Infertility in Patients Who Have Finished Treatment for Cancer

National Cancer Institute (NCI)

Unknown
96 enrolled
NCT00005590 2013-08-02

Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 3 Completed
NCT00504205 2013-08-02

MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma

National Cancer Institute (NCI)

Phase NA Terminated
30 enrolled
NCT00025129 2013-07-18

VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas

National Cancer Institute (NCI)

Phase 1 Completed
NCT00049699 2013-07-18

VNP40101M in Treating Patients With Advanced or Metastatic Cancer

National Cancer Institute (NCI)

Phase 1 Completed
NCT00103272 2013-06-04

17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer

National Cancer Institute (NCI)

Phase 1 Terminated
74 enrolled
NCT00045006 2013-05-30

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer

National Cancer Institute (NCI)

Phase 1 Completed
NCT00073944 2013-05-30

BCX-1777 in Treating Patients With Refractory Cancer

National Cancer Institute (NCI)

Phase 1 Completed